Validation of EUROArray HPV test using the VALGENT framework

The association of high-risk human papillomavirus (hrHPV) types with cervical high-grade lesions and cancer [1] has increased the use of HPV testing for cervical screening [2]. A number of HPV DNA tests detect viral nucleic acids with a variety of different read-outs [3] including those with genotyping capability. The introduction of genotyping assays in clinical practice may be useful to discriminate between hrHPV positive women at higher risk of cancer and has already been recommended as a triage of primary HPV infection in certain guidelines [4,5].

Source: Journal of Clinical Virology - September 10, 2018 Category: Virology Authors: Jessica Viti, Mario Poljak, Anja O štrbenk, Ramya Bhatia, Elia Alcañiz Boada, Alyssa M. Cornall, Kate Cuschieri, Suzanne Garland, Lan Xu, Marc Arbyn Source Type: research